These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38346967)

  • 1. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
    Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
    Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer.
    Sarwar S; Morozov VM; Newcomb MA; Yan B; Brant JO; Opavsky R; Guryanova OA; Ishov AM
    Cell Death Dis; 2024 Aug; 15(8):558. PubMed ID: 39090086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
    Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Chao OS; Goodman OB
    Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG; Agarwal N; Araujo JC; Sonpavde G
    Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
    Ruiz de Porras V; Wang XC; Palomero L; Marin-Aguilera M; Solé-Blanch C; Indacochea A; Jimenez N; Bystrup S; Bakht M; Conteduca V; Piulats JM; Buisan O; Suarez JF; Pardo JC; Castro E; Olmos D; Beltran H; Mellado B; Martinez-Balibrea E; Font A; Aytes A
    Eur Urol; 2021 Jun; 79(6):722-733. PubMed ID: 33153817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the
    Lombard AP; Lou W; Armstrong CM; D'Abronzo LS; Ning S; Evans CP; Gao AC
    Mol Cancer Ther; 2021 Oct; 20(10):2061-2070. PubMed ID: 34326198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and epigenetic aberrations of ABCB1 synergistically boost the acquisition of taxane resistance in esophageal squamous cancer cells.
    Sumarpo A; Ito K; Saiki Y; Ishizawa K; Wang R; Chen N; Sunamura M; Horii A
    Biochem Biophys Res Commun; 2020 Jun; 526(3):586-591. PubMed ID: 32247608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
    Hillowe A; Gordon C; Wang L; Rizzo RC; Trotman LC; Ojima I; Bialkowska A; Kaczocha M
    PLoS One; 2023; 18(10):e0292483. PubMed ID: 37796964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.
    Ríos-Colón L; Cajigas-Du Ross CK; Basu A; Elix C; Alicea-Polanco I; Sanchez TW; Radhakrishnan V; Chen CS; Casiano CA
    Oncotarget; 2017 Apr; 8(15):24915-24931. PubMed ID: 28212536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
    Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
    Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
    Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
    Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer.
    Sarwar S; Morozov VM; Purayil H; Daaka Y; Ishov AM
    Cell Death Dis; 2022 Oct; 13(10):868. PubMed ID: 36229449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion.
    Mitra Ghosh T; Kansom T; Mazumder S; Davis J; Alnaim AS; Jasper SL; Zhang C; Bird A; Opanasopit P; Mitra AK; Arnold RD
    J Pharmacol Exp Ther; 2022 Mar; 380(3):180-201. PubMed ID: 34949650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer.
    Archer M; Begemann D; Gonzalez-Kozlova E; Nepali PR; Labanca E; Shepherd P; Dogra N; Navone N; Kyprianou N
    Mol Cancer Res; 2024 Aug; 22(8):730-745. PubMed ID: 38648082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
    Rocha SM; Nascimento D; Coelho RS; Cardoso AM; Passarinha LA; Socorro S; Maia CJ
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.